Cartalax is a synthetic Khavinson tetrapeptide (Ala-Glu-Asp-Pro) studied for joint support and cartilage regeneration. Joint support and general health maintenance is what draws most of the community interest, and reports there skew positive; a smaller, more mixed thread centers on cartilage repair and regeneration. Reported doses run from 2 mg to 10 mg daily, most commonly 2 mg, taken daily. The honest limitation: there is no FDA-approved indication, so all human use is off-label or compounded, and the human evidence base is preclinical and animal-only.
Data last updated
Measured on 4 of 6 axes
Evidence shape
Cartalax currently lacks human clinical evidence, as all existing research is restricted to animal models and preclinical mechanistic studies. There are no registered human trials, and the available data is limited to a single indication focused on early-stage laboratory research. Because no completed human trials exist, there is no established safety or efficacy profile for use in human subjects.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How Cartalax is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
Clinician protocols dose 2 mg–5 mg daily subQ (1 source).
Most community users inject CARTALAX subcutaneously once daily (typically 2 mg, ranging from 100 µg to 10 mg); a smaller group doses weekly (about 2.5 mg) and others follow an unstated schedule, often around 5 mg.